258 related articles for article (PubMed ID: 31868223)
21. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and placental transfer of dolutegravir in pregnancy.
Ikumi NM; Anumba D; Matjila M
J Antimicrob Chemother; 2022 Feb; 77(2):283-289. PubMed ID: 34618029
[TBL] [Abstract][Full Text] [Related]
23. Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.
Jacobs TG; van Aerde KJ; Colbers A; Burger DM
Pediatr Infect Dis J; 2022 Feb; 41(2):131-132. PubMed ID: 35017453
[TBL] [Abstract][Full Text] [Related]
24. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C
Clin Pharmacol Ther; 2021 Apr; 109(4):1025-1029. PubMed ID: 33521960
[TBL] [Abstract][Full Text] [Related]
25. Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.
Wilson HI; Mapesi H
Pan Afr Med J; 2020; 37():243. PubMed ID: 33552361
[No Abstract] [Full Text] [Related]
26. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
[TBL] [Abstract][Full Text] [Related]
27. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
Mohan H; Lenis MG; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
EBioMedicine; 2021 Jan; 63():103167. PubMed ID: 33341441
[TBL] [Abstract][Full Text] [Related]
28. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD
Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.
Bukkems VE; van Hove H; Roelofsen D; Freriksen JJM; van Ewijk-Beneken Kolmer EWJ; Burger DM; van Drongelen J; Svensson EM; Greupink R; Colbers A
Clin Pharmacokinet; 2022 Aug; 61(8):1129-1141. PubMed ID: 35579825
[TBL] [Abstract][Full Text] [Related]
30. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
[TBL] [Abstract][Full Text] [Related]
31. Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.
Bade AN; McMillan JM; Liu Y; Edagwa BJ; Gendelman HE
Mol Neurobiol; 2021 Nov; 58(11):5703-5721. PubMed ID: 34390469
[TBL] [Abstract][Full Text] [Related]
32. Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
Banda FM; Powis KM; Sun S; Makhema J; Masasa G; Yee LM; Jao J
AIDS; 2020 Dec; 34(15):2336-2337. PubMed ID: 32910067
[No Abstract] [Full Text] [Related]
33. Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
Dickinson L; Walimbwa S; Singh Y; Kaboggoza J; Kintu K; Sihlangu M; Coombs JA; Malaba TR; Byamugisha J; Pertinez H; Amara A; Gini J; Else L; Heiberg C; Hodel EM; Reynolds H; Myer L; Waitt C; Khoo S; Lamorde M; Orrell C;
Clin Infect Dis; 2021 Sep; 73(5):e1200-e1207. PubMed ID: 33346335
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
[TBL] [Abstract][Full Text] [Related]
36. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.
MacBrayne CE; Castillo-Mancilla J; Burton JR; MaWhinney S; Wagner CB; Micke K; Fey J; Huntley RT; Larson B; Bushman LR; Kiser JJ
J Antimicrob Chemother; 2018 Jan; 73(1):156-159. PubMed ID: 29029135
[TBL] [Abstract][Full Text] [Related]
37. Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation.
Piscitelli J; Nikanjam M; Best BM; Acosta E; Mirochnick M; Clarke DF; Capparelli EV; Momper JD
J Acquir Immune Defic Syndr; 2022 Jan; 89(1):108-114. PubMed ID: 34629412
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects].
Wajima T; Koshiba T; Ohno K; Nishimura Y; Kobayashi H; Yoshida N; Nagashima M; Fujiwara T
Jpn J Antibiot; 2013 Feb; 66(1):1-7. PubMed ID: 23777012
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
Wang X; Cerrone M; Ferretti F; Castrillo N; Maartens G; McClure M; Boffito M
Int J Antimicrob Agents; 2019 Aug; 54(2):202-206. PubMed ID: 31002950
[TBL] [Abstract][Full Text] [Related]
40. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
